
July 28 (Reuters) - Celcuity Inc CELC.O:
CELCUITY: GEDATOLISIB + FULVESTRANT REDUCED RISK OF PROGRESSION OR DEATH BY 67% VERSUS. FULVESTRANT
CELCUITY: TOPLINE DATA FOR VIKTORIA-1 PIK3CA MUTATION COHORT IS EXPECTED BY END OF 2025
CELCUITY: EXPECTS TO SUBMIT NEW DRUG APPLICATION FOR GEDATOLISIB TO U.S. FDA IN Q4 2025
CELCUITY: CLINICALLY MEANINGFUL IMPROVEMENT IN BOTH PFS PRIMARY ENDPOINTS FROM PIK3CA WILD-TYPE COHORT OF PHASE 3 VIKTORIA-1 TRIAL
CELCUITY: GEDATOLISIB + PALBOCICLIB + FULVESTRANT REDUCED RISK OF DISEASE PROGRESSION OR DEATH BY 76% VERSUS. FULVESTRANT